Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level685 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,087 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05776355 | NKG2D CAR-NK & Ovarian Cancer | unknown | N/A | 18 | Hangzhou Cheetah Cell Therapeutics Co., LtdOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT00326456 | MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer | unknown | Phase 3 | 820 | National Cancer Institute, NaplesOTHER | 3 | Mar 27, 2023 | clinicaltrials |
| NCT00660842 | Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer(MITO-7) | unknown | Phase 3 | 800 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01061619 | Pathway to Diagnosis of Ovarian Cancer(MITO-12) | unknown | — | 400 | National Cancer Institute, NaplesOTHER | 3 | Mar 24, 2023 | clinicaltrials |
| NCT01706120 | Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab(MITO16/MANGO-2) | unknown | Phase 4 | 400 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01802749 | Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer(MITO16MANGO2b) | unknown | Phase 3 | 406 | National Cancer Institute, NaplesOTHER | 5 | Mar 24, 2023 | clinicaltrials |
| NCT03410784 | Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer(MITO28MaNGOov4) | unknown | Phase 2 | 72 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT03561207 | 3D Prediction of Patient-Specific Response(3D-PREDICT) | unknown | — | 570 | KIYATECINDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05233982 | MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer(MITO 35a) | unknown | Phase 2 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05633342 | Project CADENCE (CAncer Detected Early caN be CurEd)(CADENCE) | unknown | — | 15,000 | MiRXES Pte LtdINDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04724031 | Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer | unknown | — | 150 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05184140 | Mapping Sentinel Lymph Node in Initial Stages of Ovarian Cancer(MELISA) | unknown | N/A | 62 | Hospital Clinic of BarcelonaOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT04752865 | Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer | unknown | — | 50 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05265117 | The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort Study | unknown | — | 310 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT04438564 | Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients | unknown | N/A | 300 | China Medical University HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03321188 | Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients | unknown | Phase 2 | 20 | Andrea JewellOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05453825 | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | unknown | Phase 2 | 180 | OncXerna Theraputics, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05693974 | Early Detection of Ovarian Cancer Using Plasma Cell-free DNA Fragmentomics (Retrospective Study) | unknown | — | 130 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT05693987 | Early Detection of Ovarian Cancer Using Plasma Cell-free DNA Fragmentomics (Prospective Study) | unknown | — | 248 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02125513 | Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer(GOGER-01) | unknown | Phase 2 | 129 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 30, 2022 | clinicaltrials |
| NCT04770376 | Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab | unknown | — | 150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT03162289 | Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers(FIT2) | unknown | N/A | 150 | Charite University, Berlin, GermanyOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05642871 | DKI Combined With APT for Post-treatment Assessment of Ovarian Malignancies and Correlation With XRCC2 Gene | unknown | — | 2 | Qianqian QuOTHER | 0 | Dec 8, 2022 | clinicaltrials |
| NCT05640024 | Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR Inhibitors | unknown | — | 54 | Yonsei UniversityOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05641506 | A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer | unknown | Phase 2 | 50 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05622890 | A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer | unknown | Phase 3 | 35 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT05620654 | A Phase I Dose-finding Trial of Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin | unknown | Phase 1 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT03540017 | HIPEC After Initial CRS in Patients Who Have Received NACT | unknown | Phase 1 | 15 | Northwell HealthOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05597527 | Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | unknown | Phase 2 | 35 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05591560 | Itraconazole in Advanced Ovarian Cancer | unknown | N/A | 66 | Tanta UniversityOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT05583799 | Efficacy and Adverse Effects of Niraparib in Ovarian Cancer. | unknown | — | 222 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Oct 18, 2022 | clinicaltrials |
| NCT05576519 | Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian Carcinoma | unknown | — | 50 | Sohag UniversityOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03278717 | Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients(ICON9) | unknown | Phase 3 | 330 | University College, LondonOTHER | 4 | Sep 27, 2022 | clinicaltrials |
| NCT05537844 | Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma(BriTROC-2) | unknown | — | 250 | Liz-Anne LewsleyOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT05458973 | Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation. | unknown | — | 100 | Yonsei UniversityOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT04398446 | Effect of Hemp-CBD on Patients With CIPN(Coala-T-CBD) | unknown | Phase 2 | 56 | Main Line HealthOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05523804 | Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer(GO SOAR2) | unknown | — | 800 | NHS GrampianOTHER_GOV | 1 | Aug 31, 2022 | clinicaltrials |
| NCT04015739 | Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse(BOLD) | unknown | Phase 2 | 74 | ARCAGY/ GINECO GROUPOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05043402 | A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer | unknown | Phase 3 | 400 | OncXerna Theraputics, Inc.INDUSTRY | 0 | Aug 15, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05496517 | Ovarian Cancer Individualized Scoring System Scoring System(OCISS) | unknown | — | 1,000 | Assiut UniversityOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05479487 | Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment | unknown | Phase 2 | 132 | Xiaohua Wu MDOTHER | 0 | Jul 29, 2022 | clinicaltrials |
| NCT02562365 | Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer(ACTS) | unknown | Phase 2 | 130 | Xiaohua Wu MDOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT04864431 | Vitamin D and Pre Cachexia and Cancer Cachexia in Epithelial Ovarian Cancer(VitD) | unknown | N/A | 54 | Indonesia UniversityOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05422183 | Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer | unknown | Phase 2 | 20 | Zhongda HospitalOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05410015 | Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer | unknown | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05410028 | New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence | unknown | — | 1,000 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05385068 | A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi(t) | unknown | Phase 2 | 35 | Peking Union Medical College HospitalOTHER | 0 | May 23, 2022 | clinicaltrials |
| NCT05375526 | Magtrial: Magtrace® as Tracer for Sentinel Lymph Node Detection in Early Stage Epithelial Ovarian Cancer | unknown | N/A | 10 | Maastricht University Medical CenterOTHER | 1 | May 16, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 28, 2023source: clinicaltrials